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ABSTRACT
Introduction: Sexually transmitted infections (STI) are
a major public health problem. Condoms provide
effective protection but there are many barriers to use.
Face-to-face health promotion interventions are
resource-intensive and show mixed results. Interactive
digital interventions may provide a suitable alternative,
allowing private access to personally tailored behaviour
change support. We have developed an interactive
digital intervention (the Men’s Safer Sex (MenSS)
website) which aims to increase condom use in men.
We describe the protocol for a pilot trial to assess the
feasibility of a full-scale randomised controlled trial of
the MenSS website in addition to usual sexual health
clinical care.
Methods and analysis: Participants: Men aged 16
or over who report female sexual partners and recent
unprotected sex or suspected acute STI. Participants
(N=166) will be enrolled using a tablet computer in
clinic waiting rooms. All trial procedures will be online,
that is, eligibility checks; study consent; trial
registration; automated random allocation; and data
submission. At baseline and at 3, 6 and 12 months, an
online questionnaire will assess condom use, self-
reported STI diagnoses, and mediators of condom use
(eg, knowledge, intention). Reminders will be by email
and mobile phone. The primary outcome is condom
use, measured at 3 months. STI rates will be recorded
from sexual health clinic medical records at
12 months. The feasibility of a cost-effectiveness
analysis will be assessed, to calculate incremental cost
per STI prevented (Chlamydia or Gonorrhoea), from
the NHS perspective.
Ethics and dissemination: Ethical approval: City
and East NHS Research Ethics Committee (reference
number 13 LO 1801). Findings will be made available
through publication in peer-reviewed journals, and to
participants and members of the public via Twitter
and from the University College London eHealth
Unit website. Raw data will be made available on
request.
Trial registration number: Current Controlled
Trials. ISRCTN18649610. Registered 15 October 2013
http://www.controlled-trials.com/ISRCTN18649610.
INTRODUCTION
Men’s sexual health
Sexually transmitted infections (STI) are a
major public health problem, with high
social and economic costs.
12Condoms are
effective for prevention of STI; however,
there are many barriers to successful use, for
example, decrease in sensation, interruption
of sex, incorrect size or ﬁt, use of alcohol/
recreational drugs, anxiety affecting sexual
performance, and stigma associated with car-
rying condoms.
34The prevention of preg-
nancy is often a stronger motivation for
condom use than prevention of STI.
5
Condoms may be perceived as a barrier to
intimacy and trust,
4 and use is often lower in
established relationships.
6
Since it is men who primarily experience
many of the disadvantages of using male
condoms (eg, reduced pleasure), and have
the power to inﬂuence condom use for pene-
trative sex (since they wear condoms), preven-
tion efforts are needed to target the obstacles
to condom use that men face.
3 While there
are a variety of health promotion interven-
tions aimed at improving sexual health for
men who have sex with men (MSM), there
are fewer interventions speciﬁcally for adult
men who have sex with women (MSW),
78
despite the fact that MSW report much less
consistent condom use than MSM.
9 Men are
less likely than women to visit health
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ments,
10 11 so they may be less likely to be offered health
promotional advice or risk reduction counselling in the
context of routine appointments. Men may be reluctant
to discuss their sexual health with health professionals,
partners or friends.
12 An online intervention therefore
offers an alternative avenue to reach men.
13
Sexual health interventions
Guidance from the National Institute for Health and
Care Excellence recommends that people at high risk of
STI are offered one-to-one structured discussions to
address risk-taking,
1 and this is increasingly being
offered as part of routine care in genitourinary medi-
cine and other healthcare settings. While interventions
such as motivational interviewing can impact on sexual
behaviour,
1 in practice it is resource-intensive to train
and support staff, and difﬁcult to ﬁnd time for struc-
tured discussions in busy clinical services. A potential
alternative to such interventions is the use of interactive
digital interventions (IDI).
We deﬁne IDI as ‘Computer-based programmes that
provide information and one or more of decision
support, behaviour change support, or emotional
support for health issues’.
13 IDI require contributions
from users to produce personally relevant tailored
material and feedback. IDI are highly suitable for sexual
health promotion because access can be private,
anonymous and self-paced,
14 which may be particularly
important for men who may be reluctant to disclose a
lack of knowledge or skill. Interventions can be targeted
for speciﬁc groups (eg, by age, gender or sexuality), and
content can be tailored for individuals.
15 IDI can be
expensive to develop but offer the advantages of inter-
vention ﬁdelity
16 and the potential to reach large audi-
ences at relatively low dissemination costs.
IDI can improve sexual behaviour (including condom
use),
13 17 as well as increasing knowledge, self-efﬁcacy
and safer sex intention.
13 18 More evidence is needed to
establish effects on biological outcomes (STI) and cost-
effectiveness. The Men’s Safer Sex (MenSS) website is
an IDI which aims to increase condom use and reduce
STI in men attending sexual health clinics. The present
pilot trial aims to determine the optimum parameters of
a full-scale randomised controlled trial (RCT) to assess
the efﬁcacy of the MenSS website intervention.
OBJECTIVES
To establish the feasibility and optimal design of a full-
scale RCT to test the effect on condom use and STI
acquisition of the MenSS intervention website for men
attending sexual health clinics:
▸ Conduct a pilot trial to optimise the parameters for a
phase III RCT of usual clinical care plus the IDI com-
pared to usual clinical care only, using the primary
outcome of self-reported condom use at 3-month
follow-up.
▸ Optimise the data collection and analysis procedures for
a health economic analysis for a future Phase III RCT.
Methods and analysis
The pilot trial will be a phase II proof of concept RCT
to evaluate the effect of the MenSS IDI on increasing
condom use in addition to usual clinic care for men in
sexual health clinics.
Setting
Participants will be recruited from three sexual health
clinics: The Homerton Hospital Department of Sexual
Health, St Bartholomew’s Sexual Health Centre, and
City of Coventry Health Centre Integrated Sexual Health
Services Department. These clinics serve a diverse range
of patients in terms of age, socioeconomic status and
ethnicity.
The intervention
The MenSS website content and design was developed
based on evidence from the sexual health research lit-
erature and theories of behaviour change, qualitative
interviews with men in sexual health clinics, and discus-
sions with clinical and academic experts in sexual health
and digital technologies.
19 The development process was
iterative, with a high level of user involvement. The
intervention is designed to be delivered initially in
clinic, to make use of the time when patients are waiting
to be seen, but also providing (and encouraging) online
access after patients have left the clinic.
The MenSS intervention consists of an interactive
website. While in clinic, users will be presented with a
tailored package of website content which addresses
individual men’s barriers to condom use. The site
targets a number of inﬂuences on effective condom use,
such as:
▸ Condom knowledge (eg, about sizes and types of
condoms);
▸ Condom use skills;
▸ Difﬁculties in negotiating condom use;
▸ Inaccurate beliefs about STI risk;
▸ Social inﬂuences, such as perceived/expected
partner response;
▸ Sexual pleasure;
▸ Being caught in the ‘heat of the moment’;
▸ Alcohol and drug use.
While in clinic, users will be asked to select their own
personal barriers to condom use. This task will produce
a tailored package of information, offering solutions or
counter-arguments to barriers (including interactive
activities and quizzes, videos and case vignettes), which
will be presented prominently on the homepage. Some
content is presented to all users (eg, training in condom
use skills), and all content will be available via website
navigation tabs. Participants will be led through their tai-
lored content package sequentially, and will be asked to
set goals to change their behaviour. If wanted,
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goals, and to encourage them to visit the intervention
website again.
Procedure
Participant recruitment is designed to be self-directed,
using a touch screen tablet computer, which will be
available in the clinic waiting room. Participants will be
directed to the tablet computer via brief information
leaﬂets and posters in the waiting room, or by clinic
staff. The trial software is set up to allow participants to
be led through the steps of screening, consent, auto-
matic randomisation, data collection and intervention
viewing, without assistance from clinic staff (ﬁgure 1).
A member of the study team or the sexual health clinic
research staff will be present if needed to provide tech-
nical assistance and to answer questions about the study.
Online eligibility, consent, registration, randomisation,
data collection
The tablet computer in the clinic waiting room will
present information about the trial and an invitation to
participate. Potential participants will then be asked to
complete a screening questionnaire to determine their
eligibility for the trial. Those who are ineligible at this
point will be informed of this, and thanked for their
time. Those who are eligible will receive detailed informa-
tion regarding the study. Participants will be asked to give
informed consent by agreeing to a number of statements
(see online supplementary appendix 1: online partici-
pant information and consent). They will then be asked
to give their contact details (email address and telephone
number), in order to contact them for follow-up assess-
ments, to send them reminders to view the website, to
remind them that they are participating in the trial, and
Figure 1 Men’s Safer Sex trial software framework: online study information, consent, registration, data collection and
randomisation.
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participants for their time. Participants will also be asked
to create a password. The password will give the interven-
tion group access to the intervention website, which will
also enable collection of website usage data. It will also be
needed to access the follow-up questionnaires.
Demographic and baseline sexual health data will then
be collected. At this point, the software program will use
a computer algorithm to randomly allocate participants
to either the intervention or control conditions. This allo-
cation will be unalterable.
Follow-up data collection
At 3, 6 and 12 months after their initial clinic visit, parti-
cipants will receive an automated email asking them to
complete a follow-up questionnaire (see Outcome assess-
ment section), by clicking on a weblink to an online
questionnaire. If they do not complete the question-
naire, they will receive three further email prompts, at
1-week intervals, as well as two text messages to their
mobile phone (again including the weblink) alongside
the latter two emails. If participants still do not respond,
the researcher will telephone participants a week after
the ﬁnal email to remind them to ﬁll in the study ques-
tionnaire. Information about STI diagnoses will be col-
lected at all time points via self-report, and at 12 months
by recording diagnoses or suspected diagnoses over the
past year recorded in the clinical notes at the sexual
health clinics participants are recruited from.
Inclusion and exclusion criteria
Inclusion criteria
Men aged 16 years and above (with no upper age limit);
able to read English; with access to the internet; and at
high risk of future STI (ie, two or more partners in the
past year (male or female) and some non-condom use
in the past 3 months; or symptoms of acute STI; or
seeking treatment for an STI); and for whom at least
half of their sexual partners are female.
Exclusion criteria
HIV-positive men and men with hepatitis B or C will be
excluded, since patients with these diagnoses are likely
to receive risk reduction advice in the course of routine
clinical care. We will exclude men who have had sexual
experience only ever with males, more often with males
but at least once with a female, or no sexual experience
at all.
20
Randomisation
Once participants have been checked for eligibility,
given informed consent, and submitted baseline data,
they will be allocated by the computer algorithm ran-
domisation system to either the intervention or control
group. The participant will be informed with an auto-
mated message on the tablet computer, and this alloca-
tion will be unalterable.
Allocation concealment
Allocation will be undertaken using a concealed auto-
mated computer-based algorithm, which will be
immediate.
Participants allocated to the control condition will be
notiﬁed that they have not been selected to view the
intervention and told that they will be contacted again
in 3, 6 and 12 months to gather follow-up data. Those
allocated to the intervention condition will be directed
to the intervention website where they will be presented
with a tailored package of health promotion/behaviour
change content. Website usage (page views) will be auto-
matically recorded.
Outcome assessment
Development of the online measurement instrument
We adapted the Sexunzipped online sexual health ques-
tionnaire
21 to measure outcomes and mediators of
condom use. We selected items for inclusion based on a
literature search for established measures, and consult-
ation with experts. We conducted interviews with men in
sexual health clinics (N=11) to gain feedback on succes-
sive versions of the outcome questionnaire. Interviews
with men checked their understanding of questions, the
clarity of questions, and content suitability for the
selected measures of behavioural outcomes and media-
tors of those outcomes. On the basis of feedback, we
modiﬁed the structure and content of the outcome
questionnaire.
Mediators of behaviour change (eg, beliefs about
pleasure, motivation, knowledge, self-efﬁcacy), behav-
ioural outcomes (including condom use, STI testing,
communication with partner/s) and cumulative STI inci-
dence (self-reported and from clinical notes) will be
measured. Service use and quality of life will be mea-
sured for the cost-effectiveness analysis. The primary
outcome will be self-reported condom use at 3-month
follow-up.
Measures
In the light of evidence that measurement alone may
prompt behaviour change,
22 we will measure a limited
number of outcomes (condom use and the main media-
tors, and self-reported STI diagnoses) at baseline; we will
also assess a full range of outcomes at 3, 6 and
12 months (table 1). All assessments have a recall period
of the previous 3 months, which is the time between
follow-up assessments.
Outcome measures
The online outcome measurement instrument is detailed
in full in online supplementary appendix 2.
Demographics
Questions at baseline will collect demographic informa-
tion including age, employment status and ethnicity.
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The objective of the study is to promote condom use
with female partners, so the primary outcome is the
number of episodes of unprotected vaginal sex (without
a condom) over the previous 3 months, assessed at the
3-month follow-up. We expect the majority of change in
behaviour to occur shortly after recruitment, as we
expect users will be most likely to engage with the inter-
vention during the clinic visit.
Sexual partners
Participants will be asked to report the number and type
of sexual partners over the past 3 months (both female
and male). We will also assess the number of partners
participants have had unprotected sex with over the pre-
vious 3 months: female (vaginal and anal sex) and male
(anal sex).
Contraception use and pregnancy
Participants will be asked to indicate which types of
contraception (if any) they are using with current part-
ners. Participants will be asked whether a female partner
has been pregnant in the past 3 months, and the
outcome of that pregnancy (if known).
STI diagnoses
Participants will be asked to report STI diagnoses over
the past 3 months at every follow-up point. We will also
assess whether participants have received treatment due
to a partner being diagnosed with an STI. In order to
assess laboratory diagnoses, all STI diagnoses recorded
in sexual health clinic records (in the participating sites)
over the study period will be noted at 12 months.
Health-related quality of life
Health-related quality of life (HRQoL) will be assessed
using the EQ-5D,
23 24 which is a 5-item, 3-level question-
naire covering self-care, usual activity, anxiety and
depression, and pain and mobility. We will also use a
newly developed sexual health Quality of Life Scale,
25
and compare its performance with the EQ-5D, to assess
its suitability for outcome assessment in a sexual health
context.
Service use
Use of a variety of sexual health services over the period
of the study will be assessed (eg, sexual health clinics,
general practice, outreach services).
Measuring mediators of condom use
While it is important to assess changes in behaviour, it is
also important to assess the mediators of behaviour
change. This provides information about the mechan-
isms by which behaviour might have changed. The med-
iators measured were identiﬁed following consultation
with experts, a review of the literature, interviews with
the target population, and using the theoretical frame-
works of the COM-B model
26 and the PRIME theory of
motivation.
27
Condom use errors and problems
To ensure that condom use is ‘correct’, and to assess any
impact on condom use skills, we will assess condom use
problems at all time points, using a measure deﬁned by
Crosby et al,
28 which assesses the occurrence of 15
condom errors and problems within the past 3 months.
The scale was adapted in the light of qualitative ﬁeld-
work, to improve relevance and clarity.
Table 1 Variables assessed at each time point
Baseline measures 3-month, 6-month and 12-month follow-up assessments
Demographic details (age, occupation, ethnicity)
Sexual health outcomes
Sexual partners Sexual partners
Condom use—episodes and partners Condom use—episodes and partners
Self-reported STI diagnoses Self-reported STI diagnoses
Contraception use and pregnancy Contraception use and pregnancy
Health-related quality of life Health-related quality of life
Service use
Mediators of condom use
Motivation to use condoms Motivation to use condoms
Intentions to use condoms Intentions to use condoms
Beliefs about pleasure Beliefs about pleasure
Non-condom use due to intoxication Non-condom use due to intoxication
Evaluation of condom use
Communication
Identity
Self-efficacy
Condom problems
Knowledge
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Knowledge (of risk of STIs and condom sizes) will be
assessed using an 11-item measure, devised based on
gaps in men’s knowledge identiﬁed in the literature and
in interviews with the target population. A number of
‘true or false’ statements regarding misconceptions
about condoms and risk will be given (eg, ‘You would
know if you had an STI, without needing a test’;
‘Standard sized condoms are suitable for all men’).
Communication with partners
To assess communication with partners over a 3-month
period, we adapted the six-item Partner Communication
Scale.
29 The scale was adapted in the light of qualitative
ﬁeldwork, and the recall period was modiﬁed from 6 to
3 months, as follow-up assessments will be 3 months
apart.
Identity
To assess potential links between identity (self-
perception) and condom use,
27 we created a seven-item
scale, derived from issues relating to condom use iden-
tity that had been identiﬁed during the ﬁeldwork.
Beliefs about pleasure
Beliefs about pleasure will be assessed using an eight-
item scale, adapted from the ‘Effect of sexual experi-
ence’ subscale of the Condom Perceived Barriers
Scale.
30 The scale was adapted in the light of qualitative
ﬁeldwork, to improve relevance and clarity.
Self-efficacy
Self-efﬁcacy will be assessed using a 14-item measure,
adapted from the widely validated Brafford and Beck
Scale.
31 The scale was adapted in the light of qualitative
ﬁeldwork, to improve relevance and clarity.
Motivation, intention and evaluation of condom use
Motivation (want) and intention to use condoms, and
evaluation of condom use will be assessed using single-
item measures (Robert West, 12 September 2013, per-
sonal communication).
Alcohol and drug use
Alcohol and drug use were found in our ﬁeldwork to be
important factors in non-condom use. We therefore
included a single item assessing the number of times in
the past 3 months that participants had unprotected sex
when intoxicated.
Engagement with the intervention (patterns of website use)
We will record website usage in order to assess engage-
ment with the intervention (and whether this appears to
be related to outcomes). The software used will record
the number of times each user visits the site, the pages
visited and the time spent on each topic section.
Adverse effects
We will record any adverse impacts on sexual health out-
comes at 3, 6 and 12 months. Participants will be asked
to report whether they have experienced any adverse
impacts as a result of the study, recording this in a free
text box on each of the follow-up questionnaires.
Adverse impacts may also be identiﬁed when the
research team liaise directly with participants (eg, par-
ticipant emails or follow-up telephone calls to non-
responders to questionnaires).
Intervention development costs and trial feasibility indicators
Intervention development costs and recruitment and
retention rates will be reported.
Methods to protect against sources of bias
Participants will use the tablet computer without assist-
ance, providing baseline data that will be submitted dir-
ectly online. A study researcher will be available in the
clinic and via telephone, solely to clarify research proce-
dures and assist with technical problems. Baseline data
will be collected prior to randomisation. Once eligibility
for the study is established and baseline data are col-
lected, allocation to the intervention or control group
will be automatically randomly assigned by computer
algorithm, and this will not be changeable by partici-
pants or researchers. Subsequent outcome data will be
collected online using an emailed link to the online
outcome questionnaire. Data will be exported and ana-
lysed using ID numbers only. Participants will be aware
of their allocation to the intervention or control group,
but the automated data collection procedures protect
from researcher bias during data collection.
Maximising retention
We will follow up participants by email, texts and by
telephone:
32 33
1. Automated emails, with three further follow-up
emails at weekly intervals;
2. Two text messages—at the same time as the last two
emails;
3. Contact via telephone a week after the ﬁnal email.
We will offer participants a £10 online shopping
voucher for ﬁlling in the online questionnaires at 3 and
6 months, with a £20 voucher for the ﬁnal 12-month
follow-up questionnaire. Vouchers will be sent by email.
STATISTICAL ANALYSIS PLAN
Sample size and power calculations
This is a pilot RCT with a primary aim of assessing the
success of recruitment and retention, engagement with
the intervention, and the acceptability of trial proce-
dures to participants and clinic staff. We will also calcu-
late the effect sizes of key outcomes including condom
use over the past 3 months, to inform power calculations
for a future phase III RCT.
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the intervention on episodes of unprotected vaginal sex
over the past 3 months. A sample size of 166 participants
(83 intervention, 83 comparator, randomised 1:1
between experimental and control conditions) is
adequate to detect a reduction of 1.35 episodes of
unprotected sex with a conventional two-sided α of 0.05
and 90% power (1−β). Allowing for potential loss to
follow-up at 3 months, a sample size of 122 participants
(61 intervention, 61 comparator) is adequate to ﬁnd a
reduction of 1.35 episodes of unprotected sex with a
conventional two-sided α of 0.05 and 80% power (1−β).
In addition, this sample size is also sufﬁcient to detect a
1.65 difference in safer sex intention, and a one-point
difference in self-efﬁcacy on Likert scales, with a conven-
tional two-sided α of 0.05 and 90% power (1−β).
Data analysis
Analysis of outcomes
Analysis of sexual health outcomes will be based on all
participants according to their initial experimental allo-
cation (on an intention-to-treat analysis). Analysis for the
primary outcome will use a generalised mixed model,
with log link and Poisson/mixed error. The response
variable will be the number of episodes of unprotected
vaginal sex for each subject. Explanatory variables will
be the baseline (loge(x)) number of episodes of unpro-
tected vaginal sex and the experimental condition. The
analysis will include a generalised (random effects) over-
dispersion parameter. Comparisons of sexual health
between intervention and control groups will include
the baseline value of each outcome as subject level
explanatory variables, so that analysis is of the difference
in end point conditional on the within-subject baseline
measure. For sexual health outcomes measured only at
follow-up, we will compare effect sizes between interven-
tion and control groups alone using all available data
and describe loss to follow-up for each treatment condi-
tion. For other outcomes, analyses will be based on gen-
eralised linear models with appropriate link functions
and error structures. Statistical analyses will be described
a priori in a Statistical Analysis Plan, and the principal
analyses will be implemented independently by two
statisticians.
Mediation analyses
We will conduct a prognostic model in order to determine
whether change in any of the mediating variables (eg,
beliefs about pleasure, self-efﬁcacy) is associated with any
intervention effects. This will help to identify which ele-
ments of the website seem to be most inﬂuential.
Cost-effectiveness analysis
The principal aim of the economic data collection will
be to determine the feasibility and validity of collecting
cost and outcome data for a cost-effectiveness analysis
within a phase III trial. We will conduct an initial cost-
effectiveness analysis (CEA) of incremental cost per gain
in outcome, looking at the cost per STI prevented
(Chlamydia or Gonorrhoea), comparing intervention
participants with controls from the NHS perspective.
This will include one-way, two-way and parametric sensi-
tivity tests.
The aim of the analysis will primarily be to evaluate
whether information collected is ﬁtf o rt h ep u r p o s e ,a n d
to inform information collection in a future trial. We will
examine the feasibility of collecting cost data for interven-
tion and control participants including costs associated
with STI tests and treatments, and contract tracing, testing
and treatment. Trial subjects may access sexual health ser-
vices from a range of providers, so information from
sexual health clinic notes alone may prove unreliable. We
will therefore ask participants about sexual health-related
health service contacts over the past 12 months as part of
the self-reported outcomes. Information collected from
sexual health clinic notes will be used to assess the reliabil-
ity of the self-reported information collected. Personal
Social Services Research Unit (PSSRU) reference costs,
34
British National Formulary
35 and other national sources of
costing information will be used to calculate unit costs.
Costs associated with the maintenance of the intervention
website and updating the website will also be included.
STIs prevented will be calculated by taking account of
diagnoses recorded from clinical records at 12-month
follow-up as well as self-reported episodes for the previ-
ous year. We will calculate the cost per episode of
Chlamydia or Gonorrhoea prevented for the intervention
group versus controls. The National Institute of Health
and Care Excellence (NICE) recommends that
quality-adjusted life years (QALYs) are used as the
outcome in CEA, to allow for the comparison of results
for different CEA across disease areas. QALYs are calcu-
lated by multiplying HRQoL by the amount of time
spent in the HRQoL state. The EQ-5D is the question-
naire recommended by NICE to calculate HRQoL;
24 it
has been recognised, however, that the EQ-5D may not
be suitable for economic evaluations of public health
interventions as it may not capture the relevant informa-
tion on the full psychosocial impact of public health
interventions or be sufﬁciently sensitive for that
purpose.
36 37 We will therefore also collect data on the
performance of the Sexual QoL questionnaire
25 to
assess its suitability for use in a future large-scale RCT.
Acquisition of STI may have cost and QALYs impacts
that occur beyond the end of the trial, so it is important
that this information is accounted for as part of the
model. This is commonly achieved by a decision analyt-
ical model that has a time horizon beyond the end of
the trial and combines cost and outcome data from a
range of published sources in addition to trial informa-
tion. As a result, we will design a decision analytical
model that will take account of costs and QALYs for the
lifetime of the service users. The values in the decision
analytical model will come from a comprehensive review
of the literature including the efﬁcacy of condoms,
research to increase condom use and the incidence and
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and relevance to the UK context will be assessed to
determine the best coefﬁcients to use in the cost-
effectiveness model.
36 We will also aim to determine
utility values for the long-term QALYs outcomes asso-
ciated with STIs. The ﬁnal model will compare the
incremental cost per QALYs gained and cost per STI
prevented of the internet based intervention versus the
control group. It will be subject to one-way, two-way and
probabilistic sensitivity analyses and a cost-effectiveness
acceptability curve calculated to determine the probabil-
ity that the internet based intervention is cost-effective
for a range of values of willingness to pay for an
outcome gained.
ETHICAL ISSUES
Potential ethical issues
This project aims to encourage behaviour change to
reduce morbidity and the social and emotional costs of
STI acquisition, with the aim of beneﬁting trial partici-
pants as well as wider society. There is a risk that the
study may unintentionally exacerbate the stigma of STI
and risky behaviour for participants. We strive to be non-
judgemental about choices of lifestyle or behaviour,
respecting others’ autonomy. It could be that partici-
pants’ partners or others see the intervention website,
texts to participants’ mobile phones or email messages.
Study information makes clear to participants the nature
of study-related communications and possible risks.
However, there is a danger that this may be accessed by
others and that this leads to embarrassment or relation-
ship difﬁculties in some way. A component of the inter-
vention will focus on communication with partners, so it
is hoped that the intervention will improve the quality of
relationships rather than cause harm. Participants will
receive detailed information about the study including
risks and beneﬁts while being led through the consent
process on the trial software. Participants will be offered
the opportunity to ask the researcher any further
questions.
Informed consent form and information sheet
Informed consent will be obtained using a standardised
Participant Information Sheet and consent form (both
integrated into the trial software), which have been
approved by the London City and East ethics committee
and local NHS Research and Development ofﬁces
(see online supplementary appendix 1).
All participants included in the trial will be asked for
their consent to take part and for their contact details to
be used to communicate with them (eg, for follow-up
questionnaires, and reminders to use the website), and
for data obtained as a result of their use of the NHS ser-
vices (ie, medical records) to be used for research pur-
poses. Users will not be able to register for the study
unless they consent to all statements. We will ensure that
all research procedures meet the highest standards for
data protection and conﬁdentiality, storing data on an
encrypted server. We will give participants the contact
details for support organisations in case they are
needed, and follow protocols to ensure the safety and
well-being of participants under the age of 18 who may
be at risk of harm.
Protocol amendments
Protocol amendments will be communicated to the
funder (NIHR Health Technology Assessment pro-
gramme), the Trial Steering Committee, the Trial
Management Group, the research sponsor and to the
research ethics committee.
Ancillary and post-trial care
Trial participants who request help will be advised to
contact appropriate healthcare organisations (eg, their
general practitioner) and offered the details of appropri-
ate telephone helplines or online resources. All trial par-
ticipants (including those allocated to the control
group) will be offered access to the MenSS website at
the end of the trial, for a period of 3 months.
DISSEMINATION
The following papers will be prepared and submitted for
publication in peer-reviewed journals:
▸ Description of the development process of the
MenSS intervention website;
▸ Description of the content of the MenSS intervention
website;
▸ Main ﬁndings of the pilot trial;
▸ Findings of a qualitative process evaluation of trial
procedures;
▸ Exploration of the relationship between mediators of
condom use behaviour and outcome measures.
Findings will also be made available to participants and
members of the public via Twitter and via a weblink from
the University College London eHealth Unit website.
Author affiliations
1eHealth Unit, Research Department of Primary Care and Population Health,
University College London, London, UK
2PRIMENT Clinical Trials Unit, Research Department of Primary Care and
Population Health, University College London, London, UK
3Research Department of Clinical, Educational, and Health Psychology,
University College London, London, UK
4BICMS, Barts and The London School of Medicine & Dentistry, Barts Sexual
Health Centre, St Bartholomew’s Hospital, London, UK
5Homerton Sexual Health Services, Homerton University Hospital, London, UK
6Centre for Sexual Health and HIV Research, University College London,
London, UK
7School of Engineering and Digital Arts, University of Kent, Canterbury, UK
8Department of Infection & Population Health, University College London,
London, UK
Twitter Follow Julia Bailey at @juliavbailey and UCL eHealth Unit at
@UCLeHealth
Contributors All co-authors except SD contributed to the design of the pilot trial.
SD conducted interviews with men to refine the online outcome measure. RW,
JVB, GR, SM, CE, JA, MG, JS, CSA, GH and EM contributed to the conceptual
8 Bailey JV, et al. BMJ Open 2015;5:e007552. doi:10.1136/bmjopen-2014-007552
Open Accessdesign of the MenSS intervention website. NF designed the statistical analysis
plan and RH designed the health economic analysis plan. JVB and RW wrote the
first draft of the paper and all coauthors were involved in revising the paper, and
have given final approval of the version to be published.
Funding This work was supported by a Health Technology Assessment (HTA)
grant from the National Institute for Health Research. Ref. 10/131/01 http://
www.nets.nihr.ac.uk/projects/hta/1013101.
Competing interests None.
Patient consent Obtained.
Ethics approval The study was approved by the City and East NHS Research
Ethics Committee (Study reference number 13 LO 1801).
Provenance and peer review Not commissioned; peer reviewed for ethical
and funding approval prior to submission.
Data sharing statement Anonymised data will be available on request once
the study is complete and data have been analysed by the research team.
Open Access This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://
creativecommons.org/licenses/by/4.0/
REFERENCES
1. National Institute for Health and Clinical Excellence. One to one
interventions to reduce the transmission of sexually transmitted
infections (STIs) including HIV, and to reduce the rate of under 18
conceptions, especially among vulnerable and at risk groups.
London: National Institute for Health and Clinical Excellence, 2007.
2. Health Protection Agency. Infection report. Health Protection Report:
Weekly Report 2013 June 5;7(23) http://www.hpa.org.uk/hpr/
archives/2013/hpr2313.pdf
3. Crosby R, Milhausen R, Yarber WL, et al. Condom ‘turn offs’ among
adults: an exploratory study. Int J STD AIDS 2008;19:590–4.
4. Marston C, King E. Factors that shape young people’s sexual
behaviour: a systematic review. Lancet 2006;368:1581–6.
5. Sheeran P, Abraham C. Measurement of condom use in 72 studies
of HIV-preventive behaviour: a critical review. Patient Educ Couns
1994;24:199–216.
6. Fortenberry JD, Tu W, Harezlak J, et al. Condom use as a function
of time in new and established adolescent sexual relationships.
Am J Public Health 2002;92:211–13.
7. Exner T, Gardos PS, Seal D, et al. HIV Sexual risk reduction
interventions with heterosexual men: the forgotten group. AIDS
Behav 1999;3:347–58.
8. Townsend L, Mathews C, Zembe Y. A systematic review of
behavioral interventions to prevent HIV infection and transmission
among heterosexual, adult men in low- and middle-income
countries. Prev Sci 2013;14:88–105.
9. Glick SN, Morris M, Foxman B, et al. A comparison of sexual
behavior patterns among men who have sex with men and
heterosexual men and women. J Acquir Immune Defic Syndr
2012;60:83–90.
10. Carr-Hill R, Jenkins-Clarke S, Dixon P, et al. Do minutes count?
Consultation lengths in general practice. J Health Serv Res Policy
1998;3:207–13.
11. Green CA, Pope CR. Gender, psychosocial factors and the use of
medical services: a longitudinal analysis. Soc Sci Med
1999;48:1363–72.
12. Seymour-Smith S, Wetherell M, Phoenix A. ‘My wife ordered me to
come!’: a discursive analysis of doctors’ and nurses’ accounts of
men’s use of general practitioners. J Health Psychol 2002;7:253–67.
13. Bailey JV, Murray E, Rait G, et al. Interactive computer-based
interventions for sexual health promotion. Cochrane Database Syst
Rev 2010;(9):CD006483.
14. Kanuga M, Rosenfeld WD. Adolescent sexuality and the internet:
the good, the bad, and the URL. J Pediatr Adolesc Gynecol
2004;17:117–24.
15. Lustria MA, Cortese J, Noar SM, et al. Computer-tailored health
interventions delivered over the web: review and analysis of key
components. Patient Educ Couns 2009;74:156–73.
16. Murray E, Khadjesari Z, White IR, et al. Methodological challenges
in online trials. J Med Internet Res 2009;11:e9.
17. Noar SM, Black HG, Pierce LB. Efficacy of computer technology-
based HIV prevention interventions: a meta-analysis. AIDS
2009;23:107–15.
18. Noar SM, Pierce LB, Black HG. Can computer mediated
interventions change theoretical mediators of safer sex?
A meta-analysis. Hum Commun Res 2010;36:261–97.
19. Webster R, Bailey JV. Development of a theory-based interactive
digital intervention to improve condom use in men in sexual health
clinics: an application of qualitative methods using the behaviour
change wheel. Lancet 2013;382:S102.
20. Erens B, McManus S, Field J, et al. National survey of sexual
attitudes and lifestyles II: Technical report. National Centre for Social
Research London, 2001.
21. Bailey JV, Pavlou M, Copas A, et al. The Sexunzipped pilot trial:
optimizing the design of online randomized controlled trials. J Med
Internet Res 2013;15:e278.
22. French DP, Sutton S. Reactivity of measurement in health
psychology: how much of a problem is it? What can be done about
it? Br J Health Psychol 2010;15:453–68.
23. The EuroQoL group. EuroQol—a new facility for the measurement of
health-related quality of life. Health Policy 1990;16:199–208.
24. National Institute for Clinical Excellence. Guide to the methods of
technology appraisal. National Institute for Clinical Excellence
(NICE), 2004.
25. Ratcliffe J, Brazier J, Tsuchiya A, et al. Using DCE and ranking data
to estimate cardinal values for health states for deriving a
preference-based single index from the sexual quality of life
questionnaire. Health Econ 2009;18:1261–76.
26. Michie S, van Stralen MM, West R. The behaviour change wheel:
a new method for characterising and designing behaviour change
interventions. Implement Sci 2011;6:1–12.
27. West R, Hardy A. Theory of addiction. Wiley-Blackwell, 2006.
28. Crosby R, Sanders S, Yarber WL, et al. Condom-use errors and
problems: a neglected aspect of studies assessing condom
effectiveness. Am J Prev Med 2003;24:367–70.
29. Milhausen RR, Sales JM, Wingood GM, et al. Validation of a partner
sexual communication scale for use in HIV/AIDS prevention
interventions. J HIV/AIDS Prev Child Youth 2007;8:11–33.
30. St Lawrence JS, Chapdelaine AP, Devieux JG, et al. Measuring
perceived barriers to condom use: psychometric evaluation of the
Condom Barriers Scale. Assessment 1999;6:391–404.
31. Brafford LJ, Beck KH. Development and validation of a condom self-
efficacy scale for college students. J Am Coll Health 1991;39:219–25.
32. Nicholas A, Bailey JV, Stevenson F, et al. The Sexunzipped trial:
young people’s views of participating in an online randomized
controlled trial. J Med Internet Res 2013;15:e276.
33. Free C, Knight R, Robertson S, et al. Smoking cessation support
delivered via mobile phone text messaging (txt2stop): a single-blind,
randomised trial. Lancet 2011;378:49–55.
34. Curtis L. Unit costs of health and social care. Personal Social
Services Research Unit, 2013.
35. Joint Formulary Committee. British national formulary. 65th edn.
Pharmaceutical Press, 2013.
36. Weatherly H, Drummond M, Claxton K, et al. Methods for assessing
the cost-effectiveness of public health interventions: key challenges
and recommendations. Health Policy 2009;93:85–92.
37. Kelly MP, McDaid D, Ludbrook A, et al. Economic appraisal of public
health interventions. London: Health Development Agency, 2005.
Bailey JV, et al. BMJ Open 2015;5:e007552. doi:10.1136/bmjopen-2014-007552 9
Open Access